[ad_1]
We will add
The University of Vilnius announced on Friday that serological tests for IgM, IgG or IgA antibodies from 3 different manufacturers have been evaluated. The best results were obtained with those blood samples collected 14 to 50 days after the first symptoms or the first positive PCR test, more than 90%. IgG class antibodies were detected in blood samples.
“Once again, we have confirmed that the tests are not adequate to diagnose the disease, since they detect, for example, two out of ten samples. Who can benefit from such a diagnosis? “, Said.
15 minutes In its response, the Ministry of Health (SAM) pointed out that this means that the people or companies that currently use these rapid tests to initially assess whether a person is infected are doing it completely inappropriately, and the results obtained may be completely wrong. .
Who will use the tests will have to decide SAM
A.Žvirblienė 15 minutes He said the researchers’ work is complete: what to do with the tests will have to be decided by a team of experts with the help of SAM.
“We offer absolutely nothing, we are scientists, we have done what we know how to do. Recommendations are no longer our business, “he emphasized.
The results of the biomedical evaluation of the rapid tests have been presented by the researchers to the SAM and to the Government.
A.Žvirblienė said on Friday that one of the tested tests, AMP Diagnostics, was presented to investigators by the State Accreditation Service for Health Care Activities (VASPVT), which were manufactured by the Austrian company Ameda Labordiagnostik GmbH.
According to her, Euroimmun and InTec also studied rapid tests for coronaviruses. They have the necessary certificates.
“Four types of tests from three manufacturers have been tested because they detect different classes of antibodies,” he explained.
According to the researcher, different tests were studied to compare the results: “And in all the countries that carry out the tests, several manufacturers study. Britain, for example, has nine manufacturers. Countries with large capacities can afford it. We also do a lot of research, we work very hard and without breaks. We try to give that answer as soon as possible. “
According to A.Žvirblienė, buying recently in the world of rapid tests is a problem, especially those that are highly appreciated.
“It took us a while, it took us a while to get it, because everyone needs those validated tests,” he emphasized.
The researcher will tell more about the study at a SAM press conference scheduled for Friday afternoon.
The National Laboratory purchased the Austrian tests.
15 minutes has already written that Profarma, a company that supplies rapid tests to the National Public Health Laboratory, initially did not want to indicate which manufacturer sold the tests to Lithuania, and later declared that its producer was Profarma himself.
However, it has now become clear that the true producer of these tests is the Austrian company Ameda Labordiagnostik GmbH.
Head of the Accreditation Service Nora Ribokienė 15 minutes stated that Profarma had previously requested the service to register the manufacturer’s tests.
He stressed that EU manufacturers must register their tests in the Member State where they are established.
Under the procedure, the service contacted the manufacturer and received a response that the tests are registered.
“Evidence registered in other Member States can be placed on the Lithuanian market without additional registration,” emphasized N. Ribokienė.
He did not hide the fact that Profarma also requested evidence from two Chinese manufacturers from the service. Data were received on the registration of one of them and not on the other.
However, A.Žvirblienė 15 minutes On Friday, he claimed that evidence from that manufacturer had not been provided to investigators and that the Accreditation Service had provided investigators with only Austrian evidence.
[ad_2]
